Sarpogrelate Hydrochloride, a Selective 5-hydroxytryptamine2A Antagonist, Augments Autologous Bone Marrow Mononuclear Cell Implantation–induced Improvement in Endothelium-dependent Vasodilation in Patients With Critical Limb Ischemia | Zendy

Yukihito Higashi | Zendy; Masanori Miyazaki | Zendy; Chikara Goto | Zendy; Hiroaki Sanada | Zendy; Taijiro Sueda | Zendy; Kazuaki Chayama | Zendy

Open Access

Sarpogrelate Hydrochloride, a Selective 5-hydroxytryptamine2A Antagonist, Augments Autologous Bone Marrow Mononuclear Cell Implantation–induced Improvement in Endothelium-dependent Vasodilation in Patients With Critical Limb Ischemia

Author(s) -

Yukihito Higashi,

Masanori Miyazaki,

Chikara Goto,

Hiroaki Sanada,

Taijiro Sueda,

Kazuaki Chayama

Publication year - 2010

Publication title -

journal of cardiovascular pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.762

H-Index - 100

eISSN - 1533-4023

pISSN - 0160-2446

DOI - 10.1097/fjc.0b013e3181c37da4

Subject(s) - vasodilation , medicine , peripheral blood mononuclear cell , antagonist , endothelium , ischemia , bone marrow , critical limb ischemia , pharmacology , cardiology , vascular disease , chemistry , receptor , in vitro , arterial disease , biochemistry

The purpose of this study was to determine the effect of a combination of bone marrow mononuclear cell (BM-MNC) implantation and sarpogrelate, a selective 5-HT(2A) antagonist, on endothelial function in patients with critical limb ischemia (CLI).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog